These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22154113)

  • 41. Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.
    Gori B; Ricciardi S; del Signore E; Fulvi A; de Marinis F
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S55-60. PubMed ID: 22443258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
    Rukazenkov Y; Speake G; Marshall G; Anderton J; Davies BR; Wilkinson RW; Mark Hickinson D; Swaisland A
    Anticancer Drugs; 2009 Nov; 20(10):856-66. PubMed ID: 19657272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tyrosine kinase signal transduction inhibitors. Clinical trials.
    Scagliotti GV
    Suppl Tumori; 2002; 1(4):S34-6. PubMed ID: 12415814
    [No Abstract]   [Full Text] [Related]  

  • 44. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
    Lee CC; Shiao HY; Wang WC; Hsieh HP
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments].
    Wiewrodt R; Serke M; Grohé C; Brückl W
    Pneumologie; 2013 Sep; 67(9):494-501. PubMed ID: 24006195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
    Liu D; Yang Y; Zhao S
    J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031
    [No Abstract]   [Full Text] [Related]  

  • 47. Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
    Song T; Yu W; Wu SX
    Asian Pac J Cancer Prev; 2014; 15(1):205-13. PubMed ID: 24528028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gefitinib--a novel targeted approach to treating cancer.
    Herbst RS; Fukuoka M; Baselga J
    Nat Rev Cancer; 2004 Dec; 4(12):956-65. PubMed ID: 15573117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [ZD1839].
    Nakagawa K
    Nihon Rinsho; 2002 May; 60 Suppl 5():378-83. PubMed ID: 12101693
    [No Abstract]   [Full Text] [Related]  

  • 50. Emerging combination therapies to overcome resistance in EGFR-driven tumors.
    Ratti M; Tomasello G
    Anticancer Drugs; 2014 Feb; 25(2):127-39. PubMed ID: 24113593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?
    Overbeck TR; Griesinger F
    Dermatology; 2012; 225(2):179-82. PubMed ID: 23095682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Engelman JA; Jänne PA
    Clin Cancer Res; 2008 May; 14(10):2895-9. PubMed ID: 18483355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New advance of the molecular targeting agents in advanced non-small cell lung cancer].
    Zhang L; Cheng ZW; Gao JM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):323-9. PubMed ID: 15266840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.
    Ghosh G; Yan X; Lee AG; Kron SJ; Palecek SP
    Biosens Bioelectron; 2010 Oct; 26(2):424-31. PubMed ID: 20729058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.
    Van Zandwijk N; Baas P
    Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815
    [No Abstract]   [Full Text] [Related]  

  • 57. Overcoming resistance in non-small-cell lung cancer: A practical lesson for the medicinal chemist.
    Ribaudo G; Zanforlin E; Zagotto G
    Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800037. PubMed ID: 30101528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
    Pirl WF; Solis J; Greer J; Sequist L; Temel JS; Lynch TJ
    J Clin Oncol; 2009 Aug; 27(23):e49-50; author reply e51. PubMed ID: 19597022
    [No Abstract]   [Full Text] [Related]  

  • 59. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
    Ciardiello F
    Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
    [No Abstract]   [Full Text] [Related]  

  • 60. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
    Baselga J
    J Clin Oncol; 2002 May; 20(9):2217-9. PubMed ID: 11980990
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.